The Potential Role of Psychedelic Drugs in Mental Health Care of the Future

Psychedelic drugs that produce profound alterations in perception, emotion and self-awareness—classical compounds such as LSD, psilocybin and DMT, alongside substances that evoke phenomenologically similar states like MDMA and ketamine—have re-emerged as a promising area in psychiatry after decades of prohibition. Gründer and Jungaberle situate these agents within a broader challenge to prevailing psychopharmacological paradigms: unlike standard daily-administered psychotropics, many psychedelic interventions appear to produce rapid and sometimes sustained clinical benefit after only one or a few supervised administrations, suggesting a different model of drug–psychotherapy interaction. This paper sets out to review the current scientific status of psychedelic therapies and to outline practical and regulatory challenges for integrating them into routine mental health care. Gründer and Jungaberle aim to synthesise historical context, findings from Phase I–III studies, and implementation considerations (training, screening, treatment delivery, after‑care and public communication) to inform practitioners, researchers and regulators about key issues that must be addressed as these treatments move toward clinical approval and wider use.

The paper is presented as a narrative overview rather than a systematic review; the extracted text does not report formal search strategies, databases searched, or prespecified inclusion/exclusion criteria. Instead, the authors draw on historical sources, early and contemporary clinical studies (Phase I–III), qualitative analyses of non‑clinical and traditional contexts, and observations from clinical practice to construct their synthesis. Gründer and Jungaberle combine a brief historical review with a thematic examination of current treatment research (mechanisms, models of delivery, therapist roles), and an implementation-oriented analysis. The implementation component is organised around practical domains summarised in tables within the article (for example: referral systems, screening and individualised treatment planning, preparation, dosing session logistics, after‑care/integration and follow‑up). Because the paper is an integrative, conceptual overview, formal quality assessment or meta-analytic pooling of trial data is not described in the extracted text.

The historical review traces use of plant‑derived psychedelics in ritual and medical contexts for millennia, early 20th century identification and synthesis of compounds such as mescaline, and the rapid expansion of clinical research after the discovery of LSD in 1943. Early mid‑20th century clinical studies explored a range of psychiatric indications but were generally small, often unblinded and without control groups; research largely ceased after international prohibition in the early 1970s and resumed only from the 1990s onward in limited, phased clinical programmes. Gründer and Jungaberle contrast conventional psychopharmacology—which typically treats putative molecular deficits with continuous drug administration—with a ‘‘disruptive psychopharmacology’’ model exemplified by psychedelics. Classical psychedelics act primarily as agonists or partial agonists at the serotonin 5‑HT2A receptor, and for psilocybin the intensity of binding correlates with the subjective psychedelic state. Yet the mechanistic pathway from receptor action to profound changes in self‑experience and durable clinical benefit remains unresolved. The authors note that standard antidepressant response and remission rates are limited (for example, only about 30% remission with citalopram is cited), highlighting the clinical need that motivates psychedelic research. On the clinical programme side, the paper reports that several compounds have received regulatory attention: MDMA has been granted FDA “breakthrough” designation for PTSD and psilocybin for major depression and treatment‑resistant depression. Phase II trials demonstrated efficacy and safety for MDMA in PTSD, and the authors note that Phase III results have recently confirmed these findings, such that approval in the near future is anticipated by some stakeholders (as reported by the authors). Contemporary clinical practice and trials typically embed one or two medium‑to‑high dosing sessions within a psychotherapeutic framework: pre‑treatment screening and preparation, supervised dosing (often with one or two therapists and a music programme), and structured after‑care or integration sessions. The ‘‘set and setting’’ concept and extra‑pharmacological context are emphasised as central determinants of therapeutic outcomes. Several treatment and research issues are highlighted. Microdosing—regular small doses approximating one‑tenth of a full dose—has attracted interest but lacks randomised controlled trials in clinical populations, so whether subjective psychedelic experiences are necessary for benefit remains unanswered. Group delivery formats (from minimal interaction to active therapeutic group processes) are identified as under‑investigated alternatives to the prevailing individual supervised model. Therapist competencies are discussed as a developing area: current trials use varied psychotherapeutic approaches (from manualised CBT/third‑wave CBT to less structured facilitation), and the field lacks strong evidence about which specific therapist skills most strongly influence outcomes. The authors note debate about the importance of therapists’ own psychedelic self‑experience and anticipate a shift toward more standardised training grounded in general psychotherapy research while retaining domain‑specific skills (screening, guiding altered states, integration). Implementation‑oriented results are presented as a set of practical domains and comparisons. The authors summarise system components that require attention: referral and liaison systems, rigorous psychiatric screening (including exclusion of those with psychosis or mania and family history considerations), preparation and consent processes, supervised dosing logistics (medical oversight, facility requirements, observation periods), and after‑care/integration and follow‑up monitoring (symptom trajectories, suicidality, substance use). A tabulated comparison contrasts classical psychotropic treatment with psychedelic approaches across multiple dimensions: dosing frequency (regular daily dosing versus one to several supervised doses), patient journey complexity (expanded referral, screening, preparation and integration), temporal profile of response (often immediate for psychedelics with potential long‑term effects versus delayed response for some antidepressants), therapist–patient interaction intensity and duration, intended psychological effects (temporary destabilisation and access to autobiographical material versus stabilisation), and emphasis on existential and meaning‑making topics. The authors catalogue broader implementation challenges: absence of large‑scale quantitative implementation studies, ambivalence about mechanisms, diverse sociocultural discourses around psychedelics (clinical/regulatory versus self‑experiential/spiritual/recreational), commercial and black‑market interests, and questions about who will provide therapies when many psychedelic molecules are not patentable. Clinical areas where preliminary clinical trials have shown positive effects include major and treatment‑resistant depression, end‑of‑life anxiety, PTSD and some forms of substance‑use disorder. The paper also flags the need for health technology assessment and cost‑effectiveness studies to inform payers and policy makers.

Gründer and Jungaberle interpret their synthesis as indicating that psychedelic‑assisted therapies represent a potentially transformative but disruptive addition to mental health care. They argue that safe, effective implementation will require reconfigured treatment infrastructures that integrate pharmacological administration with specialised psychotherapeutic processes, new referral and screening pathways, supervised dosing facilities and robust after‑care and community follow‑up systems. The authors position psychedelic treatments relative to earlier research by highlighting their distinct clinical model—few supervised administrations embedded within a psychosocial context—rather than continuous substitutional pharmacotherapy. They emphasise that the therapeutic effects likely arise from an interaction of pharmacology and context (set and setting), and that current evidence from Phase I–III studies is promising but still limited in scale and mechanistic clarity. Key limitations and uncertainties acknowledged include the early stage of implementation research, the thin empirical base regarding therapist competencies and optimal treatment models, the lack of randomised controlled data on microdosing, and incomplete understanding of the neurobiological mechanisms that link receptor pharmacology to enduring psychological change. The authors also note the absence of large quantitative implementation studies that regulators would typically rely on. For practice and policy, the paper recommends a systematic health‑systems approach to implementation research, development of standardised training curricula (focusing on multi‑professional teams rather than single clinicians), careful screening and consent procedures, and the inclusion of digital monitoring and community‑based supports to mitigate risk and sustain benefits. They call for destigmatisation and public funding to support rigorous clinical and implementation studies, early comparative and cost‑effectiveness research (HTA), and open and accurate communication to patients and the public about potential benefits and risks. Finally, Gründer and Jungaberle suggest that psychedelic therapies could shift parts of psychiatry from drug‑centred care toward interventions centred on human experience and its social context, and they propose exploring complementary or non‑pharmacological means for inducing altered states (for example virtual reality) in conjunction with or as alternatives to pharmacological approaches.